Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open Encounter Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 13, 2026, 4:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409
View directory record Official record
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 1 Interventional

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

NCT02591914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Fovista™, Lucentis®, Avastin®, Eylea®
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 13, 2026, 4:24 PM EDT
Recruiting Phase 3 Interventional

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

NCT06745908
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BEhavioral EConomics for Oral Health iNnovation Trial

NCT03576326
View directory record Official record
Conditions
Toothbrushing, Dental Plaque, Parent-Child Relations, Oral Hygiene, Dental Caries
Interventions
Drawing Incentive
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 47 Months
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 13, 2026, 4:24 PM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971
View directory record Official record
Conditions
Constipation-Predominant Irritable Bowel Syndrome
Interventions
Renzapride
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years and older · Female only
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
126
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2008 · Synced Sep 13, 2026, 4:24 PM EDT
Active, not recruiting Not applicable Interventional

Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery

NCT04560712
View directory record Official record
Conditions
Resectable Colorectal Carcinoma, Resectable Digestive System Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Acupuncture Therapy, Best Practice, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 4 Interventional Results available

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Riverside, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

NCT00752258
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Not applicable Interventional

Improving Adherence to Statins Among Minority Populations

NCT02037685
View directory record Official record
Conditions
Dyslipidemia
Interventions
Motivational Interviewing (MINT), Usual Care
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 13, 2026, 4:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

NCT05555615
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 13, 2026, 4:24 PM EDT
Completed No phase listed Observational

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 13, 2026, 4:24 PM EDT
Withdrawn Early Phase 1 Interventional

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

NCT02454426
View directory record Official record
Conditions
Major Depressive Disorder, Coronary Artery Disease
Interventions
Vortioxetine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 13, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Brief Motivational Interviewing +/- Mindfulness Training for Adolescent Alcohol Use in Pediatric Primary Care

NCT07059078
View directory record Official record
Conditions
Adolescent Alcohol Use
Interventions
Brief Motivational Interviewing-based Alcohol Intervention, Smartphone App-delivered Mindfulness Training
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 17 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Baltimore, Maryland • Belcamp, Maryland • Bowie, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 13, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Not applicable Interventional

The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy

NCT04025320
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Intraneural Facilitation, Sham
Other
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 13, 2026, 4:24 PM EDT
Not yet recruiting Not applicable Interventional

Combined Circulatory and Dietary Interventions for Neuropathy

NCT07213843
View directory record Official record
Conditions
Diabete Type 2, Neuropathy, Painful
Interventions
INF® Therapy, NVIf
Other
Lead sponsor
Loma Linda University
Other
Eligibility
35 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

NCT01224106
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 13, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Orthodontic Appliances Efficiency With Remote Dental Monitoring and Artificial Intelligence Algorithms

NCT05573308
View directory record Official record
Conditions
Malocclusion, Misaligned Teeth
Interventions
Clear Aligners with Dental Monitoring, Clear Aligners
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
12 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
4
States / cities
Antioch, Illinois • Chicago, Illinois • Grayslake, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 13, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

NCT00517868
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Glendora, California • San Diego, California • Cartersville, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 13, 2026, 4:24 PM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 13, 2026, 4:24 PM EDT